Butterfly Network, Inc. (“Butterfly”), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced the FDA clearance of its next-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3.
The new device is the company’s third iteration of the world’s first semiconductor-based single-probe, whole-body ultrasound system. Butterfly iQ3 features a brand-new ergonomic design and will deliver double the data processing speed for optimized image resolution, sensitivity and penetration, as well as faster 3D capabilities to power novel, automated image capture modes: iQ Slice and iQ Fan.
In a collaborative study published in The Lancet Microbe, the team of scientists, led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute)
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S.
Butterfly iQ3 Takes Flight: Next-Gen Handheld Ultrasound Cleared by FDA
by Syed Hamza Sohail Leave a Comment
What You Should Know:
Scientists develop Australia’s first-of-its-kind next-gen mpox diagnostic tool
In a collaborative study published in The Lancet Microbe, the team of scientists, led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute)
Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S.
Pharmalittle: U.S. pharma layoffs continue to climb; senators push insulin makers for details of low-cost programs
Top of the morning to you, and a fine one it is. Blue skies and cool breezes are enveloping the Pharmalot campus, where the official